Skip to main content
. 2024 Oct 4;10(40):eado7120. doi: 10.1126/sciadv.ado7120

Fig. 5. Monkey pharmacokinetics of AM1-15 DAR4 and purified DAR2 and modification of drug-linker for solubility enable the utility of semipermeable inhibitor 11 in the context of drug-like ADC AM1-25.

Fig. 5.

(A) AM1-15 (broad DAR4) and AM1-15 DAR2 show linear pharmacokinetics in monkeys, and DAR purification to 2 reduces free payload in circulation. (B) Components of intact drug-linker 15 and aggregation profile of corresponding DAR4 AM1-15 ADC in pH 7.4 buffer as determined by SEC. VC, valine-citrulline; MC, maleimidocaproyl. (C) Components of enabling drug-linker 25 including solubilized para-aminobenzyloxy (p-ABO) spacer, valine-alanine (VA) dipeptide trigger unit and solubilized antibody attachment unit, and aggregation profile of corresponding DAR4 AM1-15 ADC in pH 7.4 buffer as determined by SEC.